Previous 10 | Next 10 |
SAN DIEGO, April 06, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced its speaker lineup for presentations at SynBioBeta’s Built with Biology Global Conference, which is being held in Oakland, Ca...
Shares of Codex DNA (NASDAQ:DNAY) closed down another ~11% today as the synthetic biology company's Q4 2021 results continue to weigh on the stock. Codex DNA (DNAY) released those results after the market close on March 23. Since then through closing Monday, shares are down 55%...
The following slide deck was published by Codex DNA, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Codex DNA, Inc. 2021 Q4 - Results - Earnings Call Presentation
Codex DNA's (DNAY -23.3%) Q4 2021 results that missed on both the top and bottom lines have led to a major decline in share price. The company's net loss widened by ~124% to ~$12.5M compared to the prior-year period. Codex DNA was hurt in the quarter by a more than doubling of total operating...
Gainers: Creative Medical Technology CELZ +99%. 4D pharma LBPS +87%. Femasys FEMY +21%. Revelation Biosciences (REVB) +19%. NeuroSense Therapeutics (NRSN) +7%. Losers: Cue Health (HLTH) -17%. Codex DNA (DNAY) -17%. PetVivo (PETV) -14%. Yumanity The...
Codex DNA, Inc. (DNAY) Q4 2021 Earnings Conference Call March 22, 2022 16:30 ET Company Participants Richard Lepke - Director, Investor Relations Todd Nelson - Chief Executive Officer Dan Gibson - Chief Technology Officer Jennifer McNealey - Chief Financial Officer Conference Call Participant...
Image source: The Motley Fool. Codex DNA, Inc. (NASDAQ: DNAY) Q4 2021 Earnings Call Mar 22, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Codex DNA, Inc. (DNAY) Q4 2021 Earnings Call Transcript
Codex DNA press release (NASDAQ:DNAY): Q4 GAAP EPS of -$0.43 misses by $0.06. Revenue of $3.08M (+58.8% Y/Y) misses by $0.75M. Shares -5%. FY 2022 Guidance: Total Revenue expected to be in the range of $19 to $21 million; Gross margin is expected to be in the range of...
SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today reported financial results for the fourth quarter and year ended December 31, 2021 and provided financial guidance for 2022. “Codex DNA...
Gainers: Semtech Corporation (NASDAQ:SMTC) +4%. Forterra (NASDAQ:FRTA) +4%. Cerus Corporation (NASDAQ:CERS) +4%. Inspirato Incorporated (NASDAQ:ISPO) +4%. Infinera Corporation (NASDAQ:INFN) +4%. Losers: Codex DNA (NASDAQ:DNAY) -6%. CureVac (NASDAQ:CVAC) -5%. CarParts...
News, Short Squeeze, Breakout and More Instantly...
Codex DNA Inc. Company Name:
DNAY Stock Symbol:
NASDAQ Market:
-- Record revenue of $6.7M in 3QFY22; Increase of 140% over $2.8M 3QFY 2021 -- BioXp® Kit Revenue increased to $884k, or 69% in 3QFY22 over 3QFY2021 -- Increases revenue guidance to $23 million to $25 million for the full year fiscal 2022 SAN DIEGO, Nov. 08, 2022 (GLOBE N...
SAN DIEGO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: DNAY), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its third quarter 2022 financial results on Tuesday, November 8, 2022, after the market closes. In conjunction ...
SAN DIEGO, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: DNAY), a leader in automated multi-omic and synthetic biology solutions, and Cellibre, a leading manufacturing technology company, today announced initiation of work under a collaboration to optimize the development and valid...